Article
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Cancer research - 1 Jan 2012
Hoeflich Klaus P, Merchant Mark, Orr Christine, Chan Jocelyn, Den Otter Doug, Berry Leanne, Kasman Ian, Koeppen Hartmut, Rice Ken, Yang Nai-Ying, Engst Stefan, Johnston Stuart, Friedman Lori S, Belvin Marcia
Abstract excerpt
Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclinical cancer models, leading to the initiation of clinical trials cotargeting these two key cancer signaling pathways. GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clinical trials as both single agents and in combination. The discovery of these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.